US 12,291,534 B2
Aminonorbornane derivative and manufacture method therefor and use thereof
Rongyao Chen, Jiangsu (CN)
Assigned to TRANSTHERA SCIENCES (NANJING), INC., Jiangsu (CN)
Appl. No. 17/279,751
Filed by TRANSTHERA SCIENCES (NANJING), INC., Jiangsu (CN)
PCT Filed Jul. 5, 2019, PCT No. PCT/CN2019/094864
§ 371(c)(1), (2) Date Mar. 25, 2021,
PCT Pub. No. WO2020/063012, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 201811153123.3 (CN), filed on Sep. 29, 2018.
Prior Publication US 2021/0332057 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 487/04 (2013.01) [A61P 35/00 (2018.01)] 16 Claims
 
1. A compound of formula I

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, a solvate, a polymorph, an ester, or an optical isomer thereof, wherein ring A is selected from one of the following structures:

OG Complex Work Unit Chemistry
R5 is hydrogen;
ring B is a substituted or unsubstituted aromatic ring or heteroaromatic ring; ring C is a substituted or unsubstituted aromatic ring or heteroaromatic ring;
L is a single bond or one of the following structures:

OG Complex Work Unit Chemistry
R1 is selected from R3 or one of the following structures:

OG Complex Work Unit Chemistry
wherein R3 being selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkynyl, substituted or unsubstituted C1-6 alkenyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C1-9 heteroaryl, substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C2-7 heterocycloalkyl;
R4 being selected from hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted C1-9 heteroaryl, substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C3-7 heterocycloalkyl;
R2 is selected from H, substituted or unsubstituted C1-3 alkyl, substituted or unsubstituted C3-7 cycloalkyl, substituted or unsubstituted C2-7 heterocycloalkyl, substituted or unsubstituted C6-10 aryl, or substituted or unsubstituted C1-9 heteroaryl; and wherein R1 and R2, along with N attached thereto, may optionally form a substituted or unsubstituted C2-7 heterocyclic ring and R3 and R4, along with N attached thereto, may optionally form a C3-7 heterocyclylamino or a C3-9 heteroarylamino.